KPV vs BPC-157

Side-by-side comparison of KPV, BPC-157 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute KPV KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide Recovery BPC-157 Body Protection Compound-157 Recovery
Basics
Molecular type Alpha-MSH C-terminal TripeptideGastric Pentadecapeptide
Amino acids 315
Molecular weight 355.4 Da1,419.5 Da
Half-life Short (hours)~4 hrs (SC)
Route(s) Subcutaneous, Oral (GI conditions), TopicalSubcutaneous, Intramuscular, Oral (research only)
Mechanism & Research
Primary mechanism KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives… BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o…
Research status Research Compound Research Compound
Evidence summary KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery. The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e…
Protocol & Dosing
Typical dose 500 mcg–2 mg/day (SC); variable oral dosing200–500 mcg per injection
Frequency Once or twice dailyOnce or twice daily
Duration 4–8 weeks4–12 weeks
Timing Any time; pre-meals for GI applicationsNear injury site when possible
Safety
Common side effects
  • Injection site redness (SC)
  • Mild skin darkening (possible — MC1R activity)
  • Headache (rare)
  • Injection site redness or bruising
  • Mild nausea (oral form)
  • Transient dizziness
  • Warmth at injection site
Contraindications
  • Known melanocortin sensitivity
  • Pregnancy (insufficient data)
  • Active melanoma (MC1R concern)
  • Active malignancy (theoretical growth stimulation concern)
  • Pregnancy (no safety data)
  • Concurrent anticoagulant therapy (caution)
Anti-doping Not Prohibited Prohibited (WADA S0)
Deeper reading
Related peptides BPC-157, LL-37, TB-500 TB-500, GHK-Cu, KPV, Pentadeca Arginate
Full profile Read full KPV profile → Read full BPC-157 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.